Current vial sizes may result in 5.8% of the Alzheimer's disease drug being thrown away, representing $1,619 in wasted Medicare spending per patient per year, reported researchers led by John Mafi ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. About 6% of Leqembi ...

A simple tweak in available vial sizes of the breakthrough Alzheimer’s drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. About 6% of Leqembi ...

Assuming conservative lecanemab uptake rates of 1.1-2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth of ...

The PEG 400 load from concomitant medications should be taken into consideration when prescribing Tepylute. Both vial sizes are now available, according to Shorla Oncology.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Current lecanemab vial sizes lead to 5.8% waste, a study suggested. An estimated $133 million to $336 million worth of ...

Assuming conservative lecanemab uptake rates of 1.1-2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth of ...

Assuming conservative lecanemab uptake rates of 1.1–2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth ...